Rezūm water vapor therapy for the treatment of patients with urinary retention and permanent catheter dependence secondary to benign prostate hyperplasia: a systematic review of the literature

Spinos, Theodoros; Katafigiotis, Ioannis; Leotsakos, Ioannis; Grivas, Nikolaos; Zabaftis, Christos; Ermidis, Dimitrios; Sfoungaristos, Stavros; Karavitakis, Markos

doi:10.1007/s00345-022-04258-y

Cited by 14 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Spinos et al 13 recently conducted a systematic review of five studies [14][15][16][17][18] that analyzed the safety and the efficacy of Rezum Similar to our study, all of the studies in the systematic review reported Rezum as a safe procedure as it was not associated with any AE Clavien-Dindo grade ≥III. However, it is important to note that our rates of urinary retention after initial TOV attempt, UTI, gross hematuria, and dysuria were considerably higher than that reported in these previous studies.…”

Section: Discussionsupporting

confidence: 77%

“…Spinos et al 13 recently conducted a systematic review of five studies 14–18 that analyzed the safety and the efficacy of Rezum regarding urinary retention relief. Unlike the present study with a follow‐up of 36 months, mean duration of follow‐up of most studies in the systematic review was at least 6 months, with the longest duration of follow‐up being 15.8 months.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of the Rezum system for the treatment of catheter‐dependent urinary retention: Three‐year real‐world outcomes in a multimorbid, multiethnic population

Babar,

Masoud,

Labagnara

et al. 2023

LUTS

View full text Add to dashboard Cite

Objectives To evaluate the long‐term real‐world efficacy and safety of Rezum for the treatment of catheter‐dependent urinary retention in a multimorbid, multiethnic population. Methods A single‐office, retrospective study was conducted on patients treated with Rezum between 2017 and 2019. Patients were included if they had catheter‐dependent urinary retention prior to treatment and at least one follow‐up within 36 months postoperatively. Patient demographics, procedural characteristics, adverse events (AEs), and outcome measures, including benign prostate hyperplasia (BPH) medication usage and postvoid residual (PVR), were collected at 3, 6, 12, and/or 36 months postoperatively. Regret was assessed at 36 months using the 5‐item Decisional Regret Scale (DRS). Results A total of 27 patients met the inclusion criteria, with the majority being Asian (29.6%), followed by non‐Hispanic Black (26.0%) and Hispanic (22.2%). Most patients (77.8%) had at least one comorbidity. Trial of void (TOV) was attempted at a median of 8 days (7, 13). Fourteen patients (51.9%) failed their initial TOV. Median time until catheter independence was 13.5 days (8.5, 28.8). Common AEs included urinary retention (51.9%), urinary tract infections (UTIs) (25.9%), and dysuria (25.9%). All cases of UTIs (7/7) and most cases of dysuria (6/7) occurred in patients who failed their initial TOV. At 36 months, there was a significant median percentage change in PVR (−100.0% [−100.0, −36.7], p = .049), and 40.4% of patients discontinued their BPH medications (p = .001). Of the 11 patients who filled out the DRS, 10 (90.9%) agreed/strongly agreed that they made the right decision. By 36 months, 4 patients (14.8%) underwent reoperation and 24 (88.9%) remained catheter‐independent. Conclusions At long‐term follow‐up, Rezum effectively treated catheter‐dependent urinary retention with minimal decisional regret. In patients with urinary retention, urologists should consider delaying TOV until 2 weeks postoperatively to maximize the likelihood of a successful TOV and minimize the risk of AEs.

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of the Rezum system for the treatment of catheter‐dependent urinary retention: Three‐year real‐world outcomes in a multimorbid, multiethnic population

Babar,

Masoud,

Labagnara

et al. 2023

LUTS

View full text Add to dashboard Cite

show abstract

“…Regarding patients with indwelling catheter, there is an important review confirming the feasibility and efficacy of Rezūm treatment. 36 Most significant trials are summarized in Table 3 .…”

Section: Water Vapor Thermal Therapy (Wvtt)mentioning

confidence: 99%

Minimally invasive surgical therapies (MISTs) for lower urinary tract symptoms (LUTS): promise or panacea?

Busetto,

Checchia,

Recchia

et al. 2023

Asian Journal of Andrology

View full text Add to dashboard Cite

The increasing importance of treatment of lower urinary tract symptoms (LUTS), while avoiding side effects and maintaining sexual function, has allowed for the development of minimally invasive surgical therapies (MISTs). Recently, the European Association of Urology guidelines reported a paradigm shift from the management of benign prostatic hyperplasia (BPH) to the management of nonneurogenic male LUTS. The aim of the present review was to evaluate the efficacy and safety of the most commonly used MISTs: ablative techniques such as aquablation, prostatic artery embolization, water vapor energy, and transperineal prostate laser ablation, and nonablative techniques such as prostatic urethral lift and temporarily implanted nitinol device (iTIND). MISTs are becoming a new promise, even if clinical trials with longer follow-up are still lacking. Most of them are still under investigation and, to date, only a few options have been given as a recommendation for use. They cannot be considered as standard of care and are not suitable for all patients. Advantages and disadvantages should be underlined, without forgetting our objective: treatment of LUTS and re-treatment avoidance.

show abstract

“…Rezūm (Water vapor thermal therapy), as a new MIST technique, ablates prostatic uses radiofrequency to create thermal energy through a jet of water vapor. It has been shown that Rezūm is a highly effective treatment for BPH patients with urinary retention and permanent catheter, with success rates ranging from 70.-100% 10 . In a study that included 197 patients with a 5-year follow-up (Rezūm II), signi cant improvement was observed in 3 months, and e ciency of the treatment was maintained over 5 years, International Prostate Symptom Score was reduced by 48%, quality of life increased 45% 11 .…”

Section: Introductionmentioning

confidence: 99%

Transurethral resection of the prostate (TURP) versus Rezūm for benign prostatic hyperplasia (BPH): prospective and comparative study

Yushanjiang,

Qu,

Zhao

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Benign prostatic hyperplasia(BPH) is the common male conditions that cause lower urinary tract symptoms disturbing patients. The treatments include pharmacologic, conventional transurethral resection of the prostate(TURP), and minimally invasive. Rezūm as a minimally invasive method has proven effective for BPH, but there is limited comparison with existing treatment modalities. Therefore, we conducted a comparison between Rezūm surgery and the TURP to assess the safety and efficacy of Rezūm. Methods Patients hospitalized at the West China Fourth Hospital for BPH were enrolled according to inclusion and exclusion criteria, with 20 undergoing TURP surgery and 20 undergoing Rezūm surgery. After one year of follow-up, we gathered comprehensive patient demographics and perioperative data and conducted postoperative evaluations including the International Prostate Symptom Score (IPSS) and Quality of Life (QOL) scores. Results After one year of follow-up, IPSS scores decreased by 57.35% in the TURP group and by 61.50% in the Rezūm group, respectively (p < 0.05). Similarly, QOL scores decreased by 63.12% and 63.92% in each respective group (p < 0.05). Notably, the Rezūm group exhibited significantly shorter operative times, reduced operative blood loss, and shorter hospital stays compared to the TURP group (p < 0.0001, p < 0.0001, p = 0.025). Three days post-surgery, the Rezūm group reported lower Numeric Rating Scale (NRS) scores compared to the TURP group (p < 0.0001), and experienced a shorter duration of hematuria (p = 0.023). Conclusions Rezūm enhanced the efficacy of BPH treatment at the one-year postoperative mark, yielding outcomes on par with those of TURP. Furthermore, Rezūm showcased notable advantages during the perioperative phase.

show abstract

Rezūm water vapor therapy for the treatment of patients with urinary retention and permanent catheter dependence secondary to benign prostate hyperplasia: a systematic review of the literature

Cited by 14 publications

References 29 publications

Efficacy and safety of the Rezum system for the treatment of catheter‐dependent urinary retention: Three‐year real‐world outcomes in a multimorbid, multiethnic population

Efficacy and safety of the Rezum system for the treatment of catheter‐dependent urinary retention: Three‐year real‐world outcomes in a multimorbid, multiethnic population

Minimally invasive surgical therapies (MISTs) for lower urinary tract symptoms (LUTS): promise or panacea?

Transurethral resection of the prostate (TURP) versus Rezūm for benign prostatic hyperplasia (BPH): prospective and comparative study

Contact Info

Product

Resources

About